Mineralocorticoid receptor antagonists in dialysis patients. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Tawada, Mitsuhiro; Suzuki, Yasuhiro; Sakata, Fumiko; Mizuno, Masashi; Ito, Yasuhiko
• Is Part Of: Renal replacement therapy. Volume 2:Issue 1(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-12
• Subjects: Mineralocorticoid receptor antagonist -- Cardiovascular disease -- Dialysis patients -- Aldosterone -- Peritoneal fibrosis; Kidneys -- Diseases -- Periodicals; Acute renal failure -- Treatment -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis -- Periodicals; 616.61406
• DOI: 10.1186/s41100-016-0077-4
• Languages: English
• ISSNs: 2059-1381

Abstract

Abstract Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized. The present review focuses on the effectiveness of MR antagonists and the risk of hyperkalemia in dialysis patients. Severe hyperkalemia due to treatment with MR antagonists in dialysis patients is not common, particularly in peritoneal dialysis (PD) patients, and the prospect of cardioprotective effects has been hopeful in both hemodialysis (HD) and PD patients. Further studies are required to establish optimal protocols for the use of MR antagonists in these patients without adverse effects.